Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
0(0%)
Results Posted
23%(3 trials)

Phase Distribution

Ph phase_1
14
93%
Ph not_applicable
1
7%

Phase Distribution

14

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
14(93.3%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(13)
Other(1)

Detailed Status

Completed13
Suspended1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 114 (93.3%)
N/A1 (6.7%)

Trials by Status

suspended17%
completed1387%
not_yet_recruiting17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07730177Phase 1

Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Not Yet Recruiting
NCT04280692Phase 1

Controlled Human Malaria Infection Transmission Model - Phase A

Suspended
NCT04250363Phase 1

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

Completed
NCT03952650Phase 1

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

Completed
NCT03707041Phase 1

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Completed
NCT03420053Phase 1

Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

Completed
NCT03496454Not Applicable

Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model

Completed
NCT02115516Phase 1

Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis

Completed
NCT01728701Phase 1

Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Completed
NCT02132299Phase 1

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Completed
NCT01771848Phase 1

Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults

Completed
NCT01624961Phase 1

Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults

Completed
NCT02237586Phase 1

Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge

Completed
NCT01086917Phase 1

Experimental Human Malaria Infection by PfSPZ

Completed
NCT01540903Phase 1

Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

Completed

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15